ReviewF1000Research2018
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 198 citations in OpenAlex.
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.Clinical pharmacology and therapeutics · 2025Trial
- Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.Journal of affective disorders · 2022Trial
- Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial.European archives of psychiatry and clinical neuroscience · 2021Trial
- The effect of ketamine on preventing postpartum depression.Journal of medicine and lifeTrial
- From depression to bone health: examining the skeletal effects of classical and rapid-acting antidepressants.The international journal of neuropsychopharmacology · 2026Review
- Dorsolateral Prefrontal Cortex Circuitry at the Intersection of Cognition and Disease.Biological psychiatry · 2026Review
- Chemotherapy-Induced Brain Damage: Mechanisms and Insights from Rodent Models.Brain sciences · 2026Review
- Impact of subanesthetic ketamine delivered via AmyloLipid nanovesicle (ALN)-based intranasal system on biobehavioral responses in an animal model of PTSD.Translational psychiatry · 2026Article
- Article
- Review
- How three different theories of depression converge at inflammation.Discover mental health · 2025Review
- Molecular Mechanisms Underlying Chronic High-Dose Ketamine-Induced Apoptosis in the Hippocampus: A Narrative Review.Neurochemical research · 2025Review
- Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation.Cells · 2025Review
- Exploring the Neuroprotective and Neuropsychiatric Symptom Management Potential of Ketamine in Alzheimer's Disease.Cureus · 2025Review
- Antidepressant effects of ershiwei roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity.Translational psychiatry · 2025Article
- Treatment-resistant depression: role of genetic factors in the perspective of clinical stratification and treatment personalisation.Molecular psychiatry · 2025Review
- The Behavioral and Neuroinflammatory Impact of Ketamine in a Murine Model of Depression and Liver Damage.International journal of molecular sciences · 2025Article
- Comprehensive view of suicide: A neuro-immune-endocrine approach.World journal of psychiatry · 2025Review
- mTORC1, the maestro of cell metabolism and growth.Genes & development · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.